LIVEN Pharma Signs MOU with China's TOFFLON
Summary
LIVEN Pharma enters MOU with TOFFLON to enhance pharmaceutical manufacturing in Pakistan, aligning with Vision 2030.
Kind of disclosure: Partnership/JV
Read the original filingKey facts
- MOU signed with TOFFLON
- Strategic partnership
- Location of MOU signing
- Shanghai
- Vision 2030 alignment
- Long-term strategic objectives
- Pending approvals and agreements
- Multiple stages required
Liven Pharma Limited (LIVEN) on Nafa
Last price Rs 39.19 · Pharmaceuticals · You can own LIVEN shares from your phone.
More LIVEN announcements
- NoticeGeneral Meetings / Briefing Sessions
- NoticeNotice of Corporate Briefing Session
- Financial resultLiven Pharma Limited reported a significant loss of Rs 7.37 million for the period ended September 30, 2026Filed as: Financial Results for the Quarter Ended September 30-2026
- NoticeBOARD MEETING FOR 1st Quarter Financials 2027
- NoticeCertified True Copy of Resolution Passed in Annual General Meeting Held 26th October 2026
- NoticeCorrection Clarification Regarding Annual Report 2026
Source: Liven Pharma Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.